Biodelivery Sci Intl (BDSI) 2.39 $BDSI Endo's (ENDP)

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 8:21 PM

Biodelivery Sci Intl (BDSI) 2.39 $BDSI

Endo's (ENDP) Pain Drug Opana ER to Face FDA Panel in Fall
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:47AM CDT
Endo International's (ENDP) pain drug is expected to come before the FDA's Advisory Committee this fall and hence the FDA will not render its decision by Jul 29.
BDSI: 2.39 (+0.06), ENDP: 15.84 (+0.39), ANIP: 56.27 (+3.48), BMY: 72.64 (+0.33)

BioDelivery Sciences to Present at the William Blair Annual Growth Stock Conference
PR Newswire - Wed Jun 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present at the William Blair Annual Growth Stock Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 15, 2016, at 11:40 AM Eastern Time at the Four Seasons Hotel in Chicago.
BDSI: 2.39 (+0.06)

BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
PR Newswire - Mon Jun 06, 10:48AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the presentation of data today at the 5th International Conference on Opioids (ICOO 2016), which takes place June 5-7, 2016 in Boston, Massachusetts. The poster is being presented by Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author.
BDSI: 2.39 (+0.06)

New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain
PR Newswire Europe - Fri Jun 03, 7:00AM CDT
Findings also show sustained pain relief with BELBUCA(TM) treatment for up to 48 weeks among chronic pain sufferers who require around-the-clock pain relief
BDSI: 2.39 (+0.06), ENDP: 15.84 (+0.39), ENL.TO: 20.10 (+0.29)

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.39 (+0.06), INSY: 13.07 (+0.29), AGIO: 48.50 (+1.43), GNCA: 4.67 (+0.98)

BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 8, 2016, at 11:00 AM Eastern Time at the Grand Hyatt in New York City.
BDSI: 2.39 (+0.06)

BioDelivery-Collegium Collaborate for Onsolis in U.S.
Zacks Equity Research - Zacks Investment Research - Thu May 12, 4:34PM CDT
BioDelivery Sciences (BDSI) and Collegium Pharmaceutical, have entered into a licensing deal for Onsolis in the U.S.
BDSI: 2.39 (+0.06), HSKA: 34.55 (+0.65), ANIP: 56.27 (+3.48), COLL: 13.70 (+0.41)

Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Thu May 12, 3:09AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $2.18 on volume of 1.6 million shares, above average daily volume of 1.2 million. In the past 52 weeks, shares of BioDelivery Sciences have traded between a low of $1.91 and a high of $9.91 and closed yesterday at $2.18, which is 14% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.6% while the 200-day MA has slid 2.5%.
BDSI: 2.39 (+0.06)

Collegium Licenses the U.S. rights to ONSOLIS(R) from BioDelivery Sciences
GlobeNewswire - Wed May 11, 3:05PM CDT
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017.
BDSI: 2.39 (+0.06), COLL: 13.70 (+0.41)

BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.
PR Newswire - Wed May 11, 3:05PM CDT
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Collegium.
BDSI: 2.39 (+0.06), COLL: 13.70 (+0.41)

BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.39 (+0.06), ENDP: 15.84 (+0.39), BSTC: 38.87 (+0.49), ARQL: 1.92 (+0.03)

BioDelivery's (BDSI) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Tue May 10, 7:50AM CDT
BioDelivery's first-quarter 2016 loss of 36 cents per share came in line with consensus estimates.
BDSI: 2.39 (+0.06)

BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:00AM CDT
-- Strategic initiatives implemented to better align BUNAVAIL® expenses with revenue as part of ongoing efforts to preserve and enhance long-term value; changes expected to result in savings of approximately $20 million through 2017
BDSI: 2.39 (+0.06)

Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.39 (+0.06), INO: 9.85 (-0.35), VVUS: 1.10 (unch), TEVA: 51.37 (+0.18), ARNA: 1.91 (+0.06), PBYI: 33.65 (+2.12)

Will BioDelivery (BDSI) Disappoint Estimates in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu May 05, 5:47PM CDT
BioDelivery Sciences (BDSI), which is set to report first-quarter 2016 results on May 10, reported a negative earnings surprise of 63.64% last quarter.
IPXL: 30.33 (+0.81), BDSI: 2.39 (+0.06), ENDP: 15.84 (+0.39), JAZZ: 145.00 (+2.06)

BioDelivery Sciences Announces Acceptance of an Abstract to the International Conference on Opioids on the Impact of a State Formulary Conversion to BUNAVAIL
PR Newswire - Fri Apr 29, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the acceptance of an abstract for presentation at the International Conference on Opioids, which takes place June 5-7, 2016 in Boston, Massachusetts. The abstract entitled, Reduced Buprenorphine/Naloxone Prescriptions Dispensed in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail: Implications for Potential Diversion, has been accepted for a poster presentation to take place on Monday, June 6. Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author, will present the data.
BDSI: 2.39 (+0.06)

U.S. Patent and Trademark Office Upholds the Validity of MonoSol Rx's US Patent No. 8,765,167 in the Face of Multiple Inter Partes Review Challenges Brought by BioDelivery Sciences International, Inc. (BDSI)
GlobeNewswire - Thu Apr 07, 7:30AM CDT
MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm(R) drug delivery technology to improve patient outcomes and to address unmet needs, today announced that the U.S. Patent and Trademark Office (USPTO) has upheld the validity of all challenged claims in U.S. Patent No. 8,765,167 (the '167 patent). The challenges to the '167 patent were asserted in four Inter Partes Review (IPR) proceedings brought by BioDelivery Sciences International, Inc. (Nasdaq:BDSI) ("BDSI"

against MonoSol Rx.
BDSI: 2.39 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson Controls FY26 Results Highlight Growth Momentum

Unpacking Johnson Controls' Fiscal 2026 Performance You know, it's not often that a company hits a home run with back-to-back quarters, but Johnson Controls (NYSE:JCI) seems to be swinging for the fences as they wrap up fiscal 2026. What we've got here is a robust set of financial results, showcasing not just growth but momentum that's got investors humming. We're talking...

EZRA Loop Fuses Human Insight and AI for Managers

Hybrid Coaching: The Future is Here If someone told me five years ago that human coaches and AI would team up to churn out better business leaders, I'd have a laugh. But here we are with EZRA Loop, an inventive mix of flesh-and-blood wisdom and algorithmic precision hitting the streets. This might seem like the latest buzzword pie in the sky to some, but there's a real...

IBM Targets AI Agent Security with New Releases

The AI Agent Surge: A Governance Challenge Platforms are hungry for AI agents, but enterprises are drowning in a sea of responsibilities. They bring in these digital workers, pumping them up like competitors puffing their chests. But there's a hitch: you can’t let these agents run wild in sensitive systems, or it’ll be chaos—like letting a bull loose in a china...

Ensign Group Faces Securities Fraud Lawsuit Amid Scandal

Ensign's Legal Storm: Investors on Edge Man, you can't ignore the weighty allegations pounding on Ensign Group's door right now. The skilled nursing giant, under the ticker NASDAQ:ENSG, is feeling the heat from a securities class action filed against them, and my gut tells me this isn't going to blow over quietly. This case sure looks like a financial tempest that could...

SoftwareOne Secures Leadership in Gartner Report Again

A Glance at SoftwareOne's Unyielding Dominance Call it a streak, call it consistency—either way, SoftwareOne's nailed it yet again, bagging the Leader spot in Gartner's Magic Quadrant for SAM Managed Services for the seventh straight year. Yep, seven years running. This ain't just a piece of paper to hang on the office wall. It's a testament to their grit in helping...

Midland, Michigan Tops 2027 Retirement Destinations

Down-to-Earth Findings for Retirees in 2027 Look, when we're talking about settling down after years of the daily grind, it's crystal clear what folks really care about: not blowing through their savings in a heartbeat. No wonder Midland, Michigan, nailed the No. 1 spot yet again in U.S. News & World Report's 2027 Best Places to Retire. And this ain't just a fluke; they...

Co-Diagnostics Nearing India TB Test Launch By 2026

Co-Diagnostics Gears Up for Indian TB Test Market Picture this: Co-Diagnostics, a molecular diagnostics player, is on the brink of a significant leap toward expanding its footprint in India with its TB test. The stage is set, with a clinical study already turning in results as solid as old boots. We're talking sensitivity hovering around 97.3% and specificity at...

Perpetua Wins $40M U.S. Army Deal: Eyes Tungsten Boost

Perpetua's Strategic Move in Mineral Exploration Forget the sleazy diner talk for a sec. We're diving into a strategic American push to revive homegrown tungsten supply. Perpetua Resources is dancing a new jig with a solid $40 million award from the U.S. Army, assisting in this military-driven goal through the Defense Ordnance Technology Consortium. Talk about a smart...

Pizza & Hope: Little Caesars Serves WV Communities

Rolling Out Dough and Kindness in West Virginia In a world that's more uncertain than a penny stock, here comes a story that'll warm even the coldest heart: Little Caesars is sending their Love Kitchen into West Virginia, aiming to serve piping hot pizza to about 8,000 folks in need. Fueled by the efforts of local franchisee Vicki Dunn-Marshall and her team, they're...

China Leads Electrification; US Faces Stagnation Risk

China Races Ahead in Electrification If you ever doubted China's resolve to lead the green charge, the latest Electrification Competitiveness Index should make you think again. They're pacing ahead, while the rest of the world seems content with playing catch-up. Created by the savvy folks over at We Mean Business Coalition with RMI's backing, this index sizes up the...